Posaconazole: Difference between revisions
From IDWiki
(→) |
No edit summary |
||
| Line 127: | Line 127: | ||
| |
| |
||
|} |
|} |
||
== Safety == |
|||
=== Adverse Events === |
|||
* Liver toxicity |
|||
** Generally transient and asymptomatic and self-limited |
|||
** See also [https://www.ncbi.nlm.nih.gov/books/NBK548934/ LiverTox] |
|||
[[Category:Triazoles]] |
[[Category:Triazoles]] |
||
Revision as of 13:24, 30 March 2022
Therapeutic Drug Monitoring
- Measure trough 7 days after starting or adjusting dose, or adjusting interacting medications, or concerns of poor adherence or absorption
- For prophylaxis, target trough >0.7 mg/L, or random level 0.35 mg/L 48 h after starting therapy
- For treatment, target trough >1 mg/L
Clinical Breakpoints
| Species | ECV (μg/mL) | Breakpoints (μg/mL) | Breakpoints (mm) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| S | SDD | I | R | S | SDD | I | R | ||
| Candida albicans | 0.06 | ≤0.06 | ≥0.12 | ||||||
| Candida dubliniensis | |||||||||
| Candida glabrata | 2 | ||||||||
| Candida guilliermondii | 0.5 | ||||||||
| Candida kefyr | 0.25 | ||||||||
| Candida krusei | 0.5 | ||||||||
| Candida lusitaniae | 0.12 | ||||||||
| Candida parapsilosis | 0.25 | ≤0.06 | ≥0.12 | ||||||
| Candida tropicalis | 0.12 | ≤0.06 | ≥0.12 | ||||||
| Cryptococcus neoformans | |||||||||
| Cryptococcus gattii | |||||||||
Safety
Adverse Events
- Liver toxicity
- Generally transient and asymptomatic and self-limited
- See also LiverTox
